Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study

Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study

Abstract Background Clinical evidence of immune checkpoint inhibitors combined with antiangiogenic drugs in patients with advanced non‐small cell lung cancer (NSCLC) was limited. Recombinant human endostatin (rh‐endostatin), an antiangiogenic drug, and camrelizumab, an anti‐PD‐1 antibody, have been...

Full description

Bibliographic Details
Main Authors: Xingxiang Pu, QianZhi Wang, Liyu Liu, Bolin Chen, Kang Li, Yu Zhou, Zengmei Sheng, Ping Liu, Yucheng Tang, Li Xu, Jia Li, Yi Kong, Fang Xu, Yan Xu, Lin Wu
Format: Article
Language:English
Published: Wiley 2023-04-01
Series:Cancer Medicine
Subjects:
anti‐angiogenesis
camrelizumab
immune checkpoint inhibitors
non‐small cell lung cancer
recombinant human endostatin
Online Access:https://doi.org/10.1002/cam4.5526

Internet

https://doi.org/10.1002/cam4.5526

Similar Items